Renal, Bladder and Prostate Cancer: An Update, Vol. 5

Author: Karl H. Kurth
Published: April 1999
Publisher: CRC Press
ISBN: 1850700818
Hardcover Book
Number of Pages: 290

Click to compare book prices for Renal, Bladder and Prostate Cancer: An Update, Vol. 5

This book represents a relatively recent update in the fields of renal, bladder, and prostate cancer. The purpose is to provide a good, consistent, and internally connected review of new developments in urologic oncology, specifically within the fields of renal, bladder, and prostate cancer. To this end, both the editors as well as the participants of this symposium have provided a concise overview of a variety of topics ranging from basic science issues to clinical controversies. This book is targeted to medical professionals, including urologic residents, practicing urologists, and urologic oncologists and researchers in the field of genitourinary oncology. The participants of the symposium, as well as the editors of this text, are all well recognized experts in their respective fields. The text is divided into four sections devoted to renal cell carcinoma, localized prostate cancer, advanced stage prostate cancer, and bladder cancer. Within each of these sections are topics which include basic science considerations, epidemiologic questions, and most prominently, controversies with respect to therapy for each of these genitourinary malignancies. This is an adequate overview of some of the current research ideas, treatment controversies, and future issues in the fields of renal, prostate, and bladder cancer. As such, its best use would be as a supplement to a more basic and comprehensive standard textbook in the field of urologic oncology for clinicians seeking more current information than found in most texts. Papers from an October 1998 conference review recent developments in the field of urological cancer, especially cancer of the kidney, the bladder, and the prostate. Coverage spans areas including interferons in metastatic renal cell carcinoma, prostate cancer in Japan, advances in radiotherapy of localized prostate cancer, antiandrogen monotherapy, new approaches to drug development in prostate cancer, gene therapy in metastatic transitional cell carcinoma of the bladder, and approaches for chemotherapy of metastatic urothelial cancer. Kurth, Karl H. (Univ of Amsterdam); Mickisch, Gerald H. (Erasmus Univ); Schroder, Fritz H. (Erasmus Univ and Academic Hospital)

Table of Contents
List of principal contributors
Foreword 1
Sect. 1 Renal cell carcinoma
1 Molecular genetics of renal cell carcinoma 5
2 Limits of cure by surgery in renal cell carcinoma 15
3 Organ-sparing surgery: magic bullet or tragic insanity? 23
4 Transabdominal or retroperitoneal approach for tumor nephrectomy: an easy choice? 31
5 Surgery for metastatic renal cell carcinoma: a matter of attitude? 39
6 Interferons in metastatic renal cell carcinoma: a tradition to be maintained? 45
7 Interleukin-2 in renal cell carcinoma 51
8 Gene therapeutic approaches for renal cell carcinoma: has the future arrived? 59
9 Cytotoxic T lymphocyte priming versus tolerance induction 69
Sect. 2 Prostate cancer, localized disease
10 Prostate cancer in Japan: what are the differences? 75
11 Decreasing prostate cancer mortality in the USA. Is the value of screening already proven? 85
12 Update on the European Randomized Study of Screening for Prostate Cancer: light at the end of the tunnel 95
13 What is the optimal strategy for early detection of prostate cancer? 103
14 How many biopsies should be taken for proper diagnosis and grading? 109
15 Accuracy of grading: can it be replaced by other prognostic tissue factors? Present and future 119
16 Is cure of prostate cancer possible in those for whom it is necessary? 131
17 Can aggressive treatment be avoided in those who may not need it? 139
18 Advances in radiotherapy of localized prostate cancer: improved effectiveness? 147
19 Minimal invasive treatment alternatives for localized prostate cancer using thermal therapy or cryosurgery 159
Sect. 3 Prostate cancer, advanced disease
20 Endocrine treatment of prostate cancer: the future after maximum androgen blockade and the role of PSA monitoring 173
21 Antiandrogen monotherapy 183
22 Quality of life in prostate cancer: preliminary results of two studies in patients with extensive disease 191
23 Intermittent endocrine therapy for prostate cancer 203
24 New approaches to drug development in prostate cancer 211
Sect. 4 Bladder cancer
25 Can intravesical chemotherapy prevent progression of superficial bladder cancer? 223
26 Is intravesical BCG superior to chemotherapy? 227
27 How long should adjuvant BCG be given? 235
28 Urinary cytokines after intravesical immunotherapy: are they predictors? 245
29 Is bladder preservation possible in transitional carcinoma of T[subscript 1]G[subscript 3]? 251
30 Orthotopic urinary diversion in transitional cell carcinoma: are there limits? 259
31 The place for systemic treatment in invasive bladder carcinoma 261
32 Gene therapy in metastatic transitional cell carcinoma of the bladder 267
33 Contemporary approaches for chemotherapy of metastatic urothelial cancer 275
Index 283

Click to compare book prices for Renal, Bladder and Prostate Cancer: An Update, Vol. 5 Renal, Bladder and Prostate Cancer: An Update, Vol. 5

Compare Shop Books - Help - About - Book Links - Book Coupons